# Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma

> **NCT04921995** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 40 (estimated)

## Conditions studied

- Recurrent Nasopharyngeal Carcinoma
- Unresectable Nasopharyngeal Carcinoma
- Chemotherapy Effect
- Immunotherapy
- Stereotactic Body Radiation Therapy (SBRT)

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT04921995
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-15
- **Primary completion:** 2022-10-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04921995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04921995, "Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04921995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*